Dr. James Malecha is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology. He also provides support on various intellectual property counseling matters.
Prior to joining the firm, Jim led medicinal chemistry groups at Kalypsys and Searle/Pharmacia. At Kalypsys, Jim directed research programs in a number of therapeutic areas, including metabolic disease, oncology, and arthritis and inflammation. He also managed the Kalypsys chemical development team and coordinated chemical outsourcing activities. At Searle/Pharmacia, Jim worked for 12 years as a group and project leader. He was a member of the COX-2 project team responsible for the discovery of Celebrex.
Jim is a co-inventor of numerous clinical candidates and two marketed products, Celebrex and Trocoxil. While in graduate school, he studied the total synthesis of a marine sponge metabolite and developed new synthetic methodologies. Jim has co-authored 15 scientific papers and is a co-inventor on 39 U.S. patents.
Dr. James Malecha is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology. He also provides support on various intellectual property counseling matters.
Prior to joining the firm, Jim led medicinal chemistry groups at Kalypsys and Searle/Pharmacia. At Kalypsys, Jim directed research programs in a number of therapeutic areas, including metabolic disease, oncology, and arthritis and inflammation. He also managed the Kalypsys chemical development team and coordinated chemical outsourcing activities. At Searle/Pharmacia, Jim worked for 12 years as a group and project leader. He was a member of the COX-2 project team responsible for the discovery of Celebrex.
Jim is a co-inventor of numerous clinical candidates and two marketed products, Celebrex and Trocoxil. While in graduate school, he studied the total synthesis of a marine sponge metabolite and developed new synthetic methodologies. Jim has co-authored 15 scientific papers and is a co-inventor on 39 U.S. patents.
- Ph.D., Organic Chemistry, Northwestern UniversityThesis: "Studies Directed Towards the Total Synthesis of Calyculin A"
- B.S., Organic Chemistry, Butler University
- U.S. Patent and Trademark Office
- Ph.D., Organic Chemistry, Northwestern UniversityThesis: "Studies Directed Towards the Total Synthesis of Calyculin A"
- B.S., Organic Chemistry, Butler University
- U.S. Patent and Trademark Office
Seattle-based Seal Rock is a privately held company that focuses on developing treatments for severe diseases with limited or no available therapies. SRT-015 is a second-generation liver-selective inhibitor that will be available in an oral formulation to treat severe acute alcoholic hepatitis as well as orphan liver diseases.
As part of the agreement, Seal Rock is eligible to receive up to €100 million, which includes regulatory, clinical, and commercial milestone payments, plus tiered royalties.
Wilson Sonsini's team advising Seal Rock includes Miranda Biven, Sai Upadhyayula, Ingo Hardt, Jim Malecha, and Christina Hoong.
For more information, please see the press release.
- Privacy Policy
- Terms of Use
- Accessibility